Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following Q2 Results; BL-8040 Continues to be Main Driver

August 20, 2015 12:40 PM

Roth Capital affirms BioLineRx (NASDAQ: BLRX) with a Buy rating and $7 price target after BLRX reported quarterly results earlier ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found